La cadena de opciones muestra datos clave de las opciones de acciones de Clearside Biomedical a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Clearside Biomedical..

Clearside Biomedical (NASDAQ:CLSD) Bolsa, Cadena de Opciones

Clearside Biomedical

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical Inc

In the current session, the stock is trading at $8.10, after a 0.50% spike. Over the past month, Controladora Vuela Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) stock increased by 13.61%, and in the past year, by 22.13%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1731940235_0.png" alt="Past Year Chart" />

<h3>Comparing Controladora Vuela P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Controladora Vuela has a lower P/E than the aggregate P/E of 15.38 of the Passenger Airlines industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731940235_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

News

Intraday Update

Markets

VLRS

P/E Ratio Insights for Controladora Vuela

Susquehanna analyst Christopher Rolland maintains Cirrus Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) with a Positive and raises the price target from $135 to $140.

Price Target

Analyst Ratings

CRUS

Susquehanna Maintains Positive on Cirrus Logic, Raises Price Target to $140

Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares are trading higher Monday. President-elect Donald Trump selected Liberty Energy CEO and Oklo board member Chris Wright as the next <a href="https://www.benzinga.com/24/11/42024837/trump-taps-liberty-energy-ceo-chris-wright-for-energy-secretary">United States energy secretary</a>.
What Happened: Trump has nominated Wright to lead the U.S. Department of Energy. Wright is the chief of oilfield services company Liberty Energy, and he also serves on Oklo&#8217;s board. 
&#8220;I am deeply honored by this nomination and opportunity to serve our country and continue the mission of bringing affordable, reliable energy to the citizens of the United States and beyond,&#8221; Wright said in a statement.
According to <a href="https://www.cnbc.com/amp/2024/11/16/trump-picks-liberty-energy-ceo-and-oklo-board-member-chris-wright-as-energy-secretary.html">CNBC</a>, Wright will also serve on Trump&#8217;s Council of National Energy. The Liberty Energy CEO is reportedly against the idea that climate change needs to be addressed by moving away from fossil fuels. 
&#8220;There is no climate crisis and we&#8217;re not in the midst of an energy transition either,&#8221; Wright reportedly said in a LinkedIn video posted last year. 
&#8220;There is no such thing as clean energy or dirty energy. All energy sources have impacts on the world both positive and negative.&#8221;
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42036010/alphabet-on-trial-doj-remedies-loom-but-analyst-sees-20-upside-as-discount-to-meta-narrows">Alphabet Braces For DOJ Remedies: Analyst Sees 20% Upside Despite &#8216;Worst Possible&#8217; Risks</a>
Co-founder and CEO of OpenAI Sam Altman also serves on the board of Oklo as chairman. It&#8217;s the only public company that Altman chairs. 
Oklo shares have rallied in recent weeks as hyperscalers increasingly look to nuclear power to meet the rising energy demands of AI data centers. The stock pulled back at the end of last week after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41991912/sam-altman-backed-oklo-reports-q3-earnings-momentum-is-building-every-week">third-quarter financial results</a>.
Oklo reported operating losses of $37.4 million since the start of the year. The company ended the quarter with $288.5 million in cash, cash equivalents and marketable securities.&nbsp;
"We are entering an era of unprecedented energy demand — rivaled perhaps only by initial conversion to electrification over a century ago. The world is now recognizing nuclear&#8217;s role in powering that future," said&nbsp;Jacob DeWitte, co-founder and CEO of Oklo.
"Momentum is building every week — regulators are modernizing, bipartisan support is growing and some of the most influential companies are investing heavily in the space."
OKLO Price Action: <a href="http://benzinga.com/quote/oklo" target="_blank" rel="noreferrer noopener">Oklo shares</a> were up 7.44% at $19.34 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: courtesy of Oklo.

Movers

OKLO

Oklo Stock Is Rising Today: What's Driving The Action?

Liberty Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) shares are trading higher premarket on Monday. The company disclosed that the Board of Directors intends to appoint William Kimble as non-executive Chairman and <a href="https://www.benzinga.com/pressreleases/24/11/b42032584/liberty-energy-inc-comments-on-nomination-of-chris-wright-as-u-s-secretary-of-energy-and-announces" target="_blank" rel="noreferrer noopener">Ron Gusek as Chief Executive Officer</a>.
The move came after President-elect Donald J. Trump nominated Liberty&#8217;s Founder, Chairman, CEO, and Director, Chris Wright, for the position of U.S.<a target="_blank" href="https://www.benzinga.com/24/11/42024837/trump-taps-liberty-energy-ceo-chris-wright-for-energy-secretary" rel="noreferrer noopener"> Secretary of Energy</a>.
The new CFO appointment is subject to U.S. Senate confirmation, and Mr. Wright will remain in his current role at Liberty until confirmation is completed.
Wright added, &#8220;Succession planning has been a priority of the Board. Having worked closely with both Bill and Ron, Liberty will be in the safest of hands upon my departure. Ron has been a close partner to me for over two decades and possesses all the criteria to ensure Liberty continues leading the industry in technology innovation and service quality while delivering growth for our valued shareholders.&#8221;
Last week, Trump said that Wright will be a part of the National&nbsp;Energy Council that will be headed by Interior Secretary-designate&nbsp;Doug Burgum, who is currently the governor of North Dakota.
The council&#8217;s main objective will be to cut down regulations and increase <a target="_blank" href="https://www.benzinga.com//node/42024837" rel="noreferrer noopener">investments to boost oil and gas production.</a>
The nomination of Wright, a key player in the fracking industry, signals Trump&#8217;s commitment to boost oil and gas production. The move could potentially lead to increased drilling activities and a greater focus on fracking, despite the U.S. already setting oil production records.
Investors can gain exposure to the stock via&nbsp;SPDR Series Trust SPDR S&amp;P Oil &amp; Gas Equipment &amp; Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XES#NYSE">XES</a>) and Invesco S&amp;P SmallCap Energy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSCE#NASDAQ">PSCE</a>).
Price Action: LBRT shares are up 2.96% at $17.40 premarket at the last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41575181/crude-oil-faces-steepest-one-day-drop-in-over-two-years-energy-stocks-plunge-prices" target="_blank" rel="noreferrer noopener">Crude Oil Faces Steepest One-Day Drop In Over Two Years, Energy Stocks Plunge: Prices&#8217; Are Likely To Remain Under Pressure,&#8217; Analyst Says</a></li>
</ul>

Equities

Large Cap

Management

LBRT

PSCE

SPDR S&P Oil & Gas Equipment & Services ETF

Liberty Energy Names New CEO As Chris Wright Prepares For US Energy Secretary Role

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and maintains $171 price target.

BNTX

Canaccord Genuity Maintains Buy on BioNTech, Maintains $171 Price Target

Keybanc analyst John Vinh maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Overweight and lowers the price target from $1075 to $700.

MPWR

Keybanc Maintains Overweight on Monolithic Power Systems, Lowers Price Target to $700

Stifel analyst Steven Wieczynski maintains Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Buy and raises the price target from $39 to $50.

Stifel Maintains Buy on Viking Holdings, Raises Price Target to $50

Canaccord Genuity analyst George Gianarikas maintains Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) with a Hold and maintains $2.2 price target.

SRFM

Canaccord Genuity Maintains Hold on Surf Air Mobility, Maintains $2.2 Price Target

Stifel analyst Matthew Sheerin initiates coverage on Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy rating and announces Price Target of $28.

Initiation

INGM

Stifel Initiates Coverage On Ingram Micro Holding with Buy Rating, Announces Price Target of $28

SINTX Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares are trading higher by 35% to $2.76 Monday morning after the company announced plans to buy back up to <a href="https://www.benzinga.com/pressreleases/24/11/g42031598/sintx-technologies-announces-stock-repurchase-program">$500K worth of common stock</a> in the upcoming quarters which can reduce the total shares outstanding by approximately 20%.
What Else: In general, a buyback program signals that management may believe the stock is undervalued and has confidence in the company's future performance.
"We believe that the current market undervalues SINTX's potential," said Eric Olson, CEO of SINTX Technologies. "This repurchase program underscores our confidence in the company's strategic initiatives and our commitment to delivering value to our shareholders.&#8221; 
&#8220;By leveraging our strong balance sheet, we are taking a proactive approach to capital allocation, similar to other companies in our industry that have successfully implemented share repurchase programs," Olson concluded.
Read Also: <a href="https://www.benzinga.com/24/11/42032477/spirit-airlines-eyes-financial-stability-with-chapter-11-filing-and-equity-injection">Spirit Airlines Eyes Restructuring With Chapter 11 Filing And Equity Injection</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SINT has a 52-week high of $105.80 and a 52-week low of $2.01.

SINT

Why SINTX Technologies Stock Is Up 50%

Canaccord Genuity analyst Brian McNamara maintains Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) with a Hold and raises the price target from $91 to $94.

Canaccord Genuity Maintains Hold on Spectrum Brands Holdings, Raises Price Target to $94

Stifel analyst Nathan Jones downgrades Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) from Buy to Hold and maintains the price target from $691 to $691.

Downgrades

Stifel Downgrades Parker Hannifin to Hold, Maintains Price Target to $691

Canaccord Genuity analyst Joseph Vafi maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Hold and maintains $205 price target.

GLOB

Canaccord Genuity Maintains Hold on Globant, Maintains $205 Price Target

Stifel analyst Nathan Jones downgrades Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) from Buy to Hold and lowers the price target from $112 to $107.

Stifel Downgrades Ingersoll Rand to Hold, Lowers Price Target to $107

Canaccord Genuity analyst Sumant Kulkarni maintains GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) with a Buy and lowers the price target from $31 to $28.

GHRS

Canaccord Genuity Maintains Buy on GH Research, Lowers Price Target to $28

Stifel analyst Nathan Jones downgrades ESAB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESAB#NYSE">ESAB</a>) from Buy to Hold and lowers the price target from $138 to $130.

ESAB

Stifel Downgrades ESAB to Hold, Lowers Price Target to $130

Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) shares have surged 12% to $46.80 in November, fueled by investor optimism following Donald Trump's presidential election win and the expectation of favorable economic policies for the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">banking industry</a>. 
What To Know: Trump's agenda, including potential tax cuts and regulatory rollbacks, is anticipated to create a supportive environment for financial institutions. Lower corporate taxes would allow Bank of America to retain more earnings, which could be used to expand lending operations, return capital to shareholders, or invest in new technologies.
Trump's focus on deregulation, including easing restrictions under the Dodd-Frank Act, is another positive for Bank of America. Reduced compliance costs and increased operational flexibility would allow the bank to grow its retail and commercial lending segments more aggressively. This could translate into higher revenues, particularly as businesses seek financing to capitalize on economic growth.
Additionally, Trump's infrastructure spending plans may spur demand for corporate credit and advisory services, further bolstering Bank of America's revenues. 
Meanwhile, potential inflationary pressures under Trump's policies could keep interest rates higher, boosting the bank's net interest margins and profitability on loans.
Read Also: <a href="https://www.benzinga.com/24/11/42033047/us-stocks-likely-to-open-on-a-tentative-note-as-investors-gear-up-for-nvidia-retail-earnings-analyst-updates-sp-500-target-for-2025-says-market-is-expensive">US Stocks On Edge As Investors Gear Up For Nvidia, Retail Earnings</a>
<h2 class="wp-block-heading">Is BAC A Good Stock To Buy?</h2>
Wall Street analysts view Bank of America on the whole as an Outperform, given the history of coverage over the past three months. Keith Horowitz from Citigroup in Bank of America is the most optimistic, expecting a 17.39% rise in the stock in the coming year.
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Bank of America rose 20.27%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 0.68% over the past year.
A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga PRO</a>. Try it for free.
BAC has a 52-week high of $46.84 and a 52-week low of $29.22.

What's Going On With Bank Of America (BAC) Shares

Canaccord Genuity analyst Joseph Vafi maintains CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) with a Buy and raises the price target from $9 to $10.

CINT

Canaccord Genuity Maintains Buy on CI&T, Raises Price Target to $10

<a href="https://www.bloomberg.com/news/articles/2024-11-18/goldman-readies-plans-to-spin-out-its-digital-assets-platform?srnd=homepage-europe" title="https://www.bloomberg.com/news/articles/2024-11-18/goldman-readies-plans-to-spin-out-its-digital-assets-platform?srnd=homepage-europe">https://www.bloomberg.com/news/articles/2024-11-18/goldman-readies-plans-to-spin-out-its-digital-assets-platform?srnd=homepage-europe</a>

'Goldman Readies Plans To Spin-Out Its Digital Assets Platform' - Bloomberg News

Dear Whitestone REIT Board of Trustees:
MCB Real Estate ("MCB" or "we") delivered an attractive, fully-financed proposal to the Whitestone Board to acquire Whitestone for $15 per share in an all-cash transaction. Our proposal would maximize value to Whitestone's shareholders, delivering immediate and certain value in the form of a 14.5% premium to Whitestone's share price prior to our initial proposal on June 3, 2024, and a 61.8% premium to Whitestone's unaffected share price prior to the rumored Fortress proposal on October 26, 2023. We have made repeated efforts to engage with the Whitestone Board over the last several months, but each of those attempts has been summarily rebuffed. The Board's refusal to grant due diligence, engage in any meaningful discussions, or commence a strategic alternatives process is not consistent with its duties and indicates a boardroom culture of entrenchment.
While we continue to believe our proposal is the best path forward for shareholders, our attempts to engage have been rebuffed at every turn, so we are withdrawing our proposal to acquire Whitestone at this time.
This is not a decision taken lightly. We are disappointed and disturbed at the Board's intransigence, entrenchment and apparent self-interest. The Company's recent public comments make it painfully clear that the Board is not open-minded or even willing to give real consideration to opportunities to advance shareholders' best interests.
Just a few weeks ago, Whitestone defended its entrenched position with unsupported and unrealistic claims of Whitestone's greater hypothetical "intrinsic value." Notably, however, that value was not actually provided, proven or even explained. Whitestone also attempted to rationalize the Board's refusal to consider alternatives by relying on a period of stock price outperformance that was driven by multiple acquisition rumors and proposals, including ours, that inflated Whitestone's share price.
When pressed on whether the Board is open to opportunities to enhance value on Whitestone's third quarter 2024 earnings call, Whitestone CEO David Holeman falsely asserted that the Board is actively looking at strategic options. Further, he seemingly didn't even understand what such a process to maximize value would actually entail. When asked, he said:
"I would tell you that our board reviews the best things for shareholders all the time. So we are actively looking at what are the best ways to add value, what are the best ways to produce a return to our shareholders. So I think we are actively doing that just like we should, and so I'm not sure I'm clear with your question."
Given the Board's refusal to engage with us regarding our proposal or conduct a process to explore whether other parties may have an interest in transacting with Whitestone, Mr. Holeman's comments are at best a naïve sidestep to the question, and at worst a downright lie to shareholders.
We have heard from a number of other shareholders that they are supportive of a potential transaction and share our frustration with the Whitestone Board. We believe some of these shareholders have reached out to Whitestone directly to demand answers. Unfortunately, it appears that the Whitestone Board has ignored these concerns and refused to engage with them, just as it has consistently refused to engage with MCB.
As Whitestone's largest actively managed shareholder, with ownership of 4,690,000 shares representing 9.4% of Whitestone's common shares, we note the addition of Kristian M. Gathright and Donald A. Miller to the Whitestone Board. Ms. Gathright and Mr. Miller are two new and well-regarded independent trustees whom we hope will bring fresh perspective to the Board and ensure that the Whitestone Board acts in accordance with its fiduciary duties, including taking appropriate steps to maximize value for Whitestone shareholders.
The reputations and careers of these professionals, as well as the rest of the Board, are on the line, and we call on them to act in shareholders' best interests. We believe the inherent disadvantages of Whitestone as a standalone company, and the upside for shareholders from a well-run strategic review process, are obvious.
As we have said from the onset of this process, our interests are aligned with other Whitestone shareholders. Whitestone shareholders deserve a board that is committed to considering all opportunities to maximize value. If the Whitestone Board continues its pattern of delay and entrenchment, MCB believes the entire Board should be removed at the next annual meeting of shareholders.
While we are withdrawing our proposal at this time, we remain a significant shareholder of the company and will continue to consider all options available to MCB and other Whitestone shareholders to ensure that the Board upholds its responsibilities.
Sincerely,
/s/ P. David Bramble
P. David Bramble, Managing Partner

MCB Withdraws $15/Share Whitestone REIT Acquisition Proposal, Criticizes Board Entrenchment; Calls For Strategic Review To Maximize Shareholder Value

Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Clearside Biomedical (CLSD – Research Report). The associated price...

Buy Rating on Clearside Biomedical: Promising ODYSSEY Trial Results and Undervalued Market Position

Needham analyst Serge Belanger has maintained their bullish stance on CLSD stock, giving a Buy rating today. Serge Belanger has given his Buy ratin...

Buy Rating Affirmed with Increased Price Target for Clearside Biomedical Post-ODYSSEY Trial Success

Clearside stock falls 12% amid Phase 2 data for CLS-AX

Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report) and keeping the price targe...

Clearside Biomedical's CLS-AX Shows Promising Phase 2b Results for Wet AMD, Justifying a Buy Rating with a $6.00 Target

Clearside Biomedical (CLSD) announced that multiple presentations were delivered at the 2024 Annual Meeting of the American Academy of Ophthalmolog...

Clearside Biomedical announces multiple presentations delivered at 2024 AAO

Clearside Biomedical GAAP EPS of -$0.10 beats by $0.02, revenue of $1.03M beats by $0.91M

Reports Q3 revenue $1.04M, consensus $120,000. "We are making outstanding progress advancing our differentiated suprachoroidal delivery pipeline," ...

Clearside Biomedical reports Q3 EPS (10c), consensus (12c)

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Clearside Biomedical Inc ( ($CLSD) ) has released its Q3 earnings. Here is a breakdown of the information Clearside Biomedical Inc presented to its...

Clearside Biomedical Reports Positive Q3 2024 Results

Clearside Biomedical (CLSD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatt...

Promising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash Position

CLSD

Press Releases

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Earnings

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Health Care

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Comments

Clearside Biomedical

Clearside Biomedical (CLSD) Opciones

Clearside Biomedical (NASDAQ:CLSD) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL